Amicus Therapeutics, Inc. Insider Trading

FOLD

Last 12 months

Insiders sold $5.17M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Nov 2021.

Net open-market

−$5.17M

0 buys · 10 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Nov 2021

Nov 1, 2021

Get an email when FOLD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Mar 2	Bradley L Campbell President and CEO	Sold10b5-1 plan	22,500	$14.35	323K	2.2%	Form 4
Jan 20	Bradley L Campbell President and CEO	Sold10b5-1 plan	75,000	$14.31	$1.07M	6.8%	Form 4
Dec 19, 2025	David Michael Clark Chief People Officer	Sold10b5-1 plan	25,642	$14.17	363K	9.5%	Form 4
Dec 15, 2025	Bradley L Campbell President and CEO	Sold10b5-1 plan	77,926	$10.86	846K	6.5%	Form 4
Dec 15, 2025	David Michael Clark Chief People Officer	Sold10b5-1 plan	25,643	$11.00	282K	8.6%	Form 4
Dec 1, 2025	Bradley L Campbell President and CEO	Sold10b5-1 plan	14,587	$10.01	146K	1.3%	Form 4
Nov 24, 2025 – Nov 26, 2025	Ellen Rosenberg Chief Legal Officer	Sold10b5-1 plan 3 parts	95,621	$10.02 average	958K	15%	Form 4
Nov 24, 2025	Jeff Castelli Chief Development Officer	Sold10b5-1 plan	76,158	$10.16	774K	15%	Form 4
Nov 24, 2025	David Michael Clark Chief People Officer	Sold10b5-1 plan	25,643	$10.10	259K	7.9%	Form 4
Nov 24, 2025	Bradley L Campbell President and CEO	Sold10b5-1 plan	14,587	$10.04	146K	1.3%	Form 4
Nov 4, 2025	David Michael Clark Chief People Officer	Sold10b5-1 plan	25,643	$9.51	244K	7.4%	Form 4
Feb 19, 2025	Bradley L Campbell President and CEO	Sold10b5-1 plan	400	$10.00	4K	<0.1%	Form 4
Dec 2, 2024	Bradley L Campbell President and CEO	Sold10b5-1 plan	7,500	$10.02	75K	0.8%	Form 4
Nov 6, 2024	Bradley L Campbell President and CEO	Sold10b5-1 plan	7,901	$12.50	99K	0.9%	Form 4

Mar 210b5-1 plan
Bradley L Campbell
President and CEO · sold 22,500 at $14.35
323K
2.2% of stake
Jan 2010b5-1 plan
Bradley L Campbell
President and CEO · sold 75,000 at $14.31
$1.07M
6.8% of stake
Dec 19, 202510b5-1 plan
David Michael Clark
Chief People Officer · sold 25,642 at $14.17
363K
9.5% of stake
Dec 15, 202510b5-1 plan
Bradley L Campbell
President and CEO · sold 77,926 at $10.86
846K
6.5% of stake
Dec 15, 202510b5-1 plan
David Michael Clark
Chief People Officer · sold 25,643 at $11.00
282K
8.6% of stake
Dec 1, 202510b5-1 plan
Bradley L Campbell
President and CEO · sold 14,587 at $10.01
146K
1.3% of stake
Nov 24, 2025 – Nov 26, 202510b5-1 plan
Ellen Rosenberg
Chief Legal Officer · sold 95,621 at avg $10.02
958K
15% of stake
Nov 24, 202510b5-1 plan
Jeff Castelli
Chief Development Officer · sold 76,158 at $10.16
774K
15% of stake
Nov 24, 202510b5-1 plan
David Michael Clark
Chief People Officer · sold 25,643 at $10.10
259K
7.9% of stake
Nov 24, 202510b5-1 plan
Bradley L Campbell
President and CEO · sold 14,587 at $10.04
146K
1.3% of stake
Nov 4, 202510b5-1 plan
David Michael Clark
Chief People Officer · sold 25,643 at $9.51
244K
7.4% of stake
Feb 19, 202510b5-1 plan
Bradley L Campbell
President and CEO · sold 400 at $10.00
4K
<0.1% of stake
Dec 2, 202410b5-1 plan
Bradley L Campbell
President and CEO · sold 7,500 at $10.02
75K
0.8% of stake
Nov 6, 202410b5-1 plan
Bradley L Campbell
President and CEO · sold 7,901 at $12.50
99K
0.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch FOLD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with FOLD

CompareIntrinsic value

MIRMMirum Pharmaceuticals Inc.

$95.00+9.16%30

ARWRArrowhead Pharmaceuticals Inc.

$61.65+3.56%40

CPRXCatalyst Pharmaceuticals Inc.

No recent price73

TVTXTravere Therapeutics Inc.

$52.64+6.54%52

OPKOpko Health Inc.

$1.77+2.91%25

BBIOBridgeBio Pharma, Inc.

$77.89+5.21%30

RAREUltragenyx Pharmaceutical Inc.

$17.16+3.19%40

HCMHUTCHMED (China) Ltd

$13.92+6.42%45

Spot a number that looks wrong? Check it in FOLD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing FOLD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.